Alpha-1 Antitrypsin Deficiency Management

Diagnostic Thresholds and Interpretation

The American Thoracic Society recommends that patients with severe deficiency of Alpha-1 Antitrypsin (A1AT) levels (<11 mmol/L or <0.57 g/L) are at markedly increased risk for COPD and emphysema 1, 2
The Canadian Thoracic Society suggests an intermediate threshold of <23 mmol/L (<1.2 g/L) for A1AT levels, which warrants genetic testing in patients with moderate clinical suspicion 1

The Canadian Thoracic Society conditionally recommends augmentation therapy for patients with A1AT deficiency who meet specific criteria, including never or former smokers, FEV1 <80% predicted, documented emphysema, and severely reduced functional A1AT level (<11 mmol/L or <0.57 g/L) 1
Augmentation therapy should be offered to patients with low A1AT levels (<11 mmol/L or <0.57 g/L) and documented COPD with emphysema, if they are never or former smokers (smoke-free ≥6 months), have FEV1 <80% predicted, documented SERPINA1 deficiency genotypes, and are on optimal COPD therapy 1

The American Thoracic Society recommends that all patients with COPD require standard management, including bronchodilators, inhaled corticosteroids, antibiotics, pulmonary rehabilitation, and supplemental oxygen, regardless of A1AT levels 1, 3

Smoking cessation is the single most important intervention for patients with A1AT deficiency and must be achieved before considering augmentation therapy, with smokers having a life expectancy <20 years after diagnosis 1, 3
Annual influenza vaccination, pneumococcal vaccination, and hepatitis B vaccination are recommended for patients with A1AT deficiency 3

Patients with heterozygous states (PiMZ, PiSZ) are at lower risk than those with Pi*ZZ phenotype but still require management focused on smoking cessation and standard COPD therapy 3
Monitoring during augmentation therapy should include annual spirometry to assess FEV1 decline and CT imaging to monitor emphysema progression 1, 3

The American Thoracic Society recommends initiating early antibiotic therapy for all purulent exacerbations due to increased elastolytic burden risk in A1AT deficiency, and using brief courses of systemic corticosteroids during acute exacerbations 4
The American Thoracic Society suggests counseling on avoidance of environmental pollutants and occupational exposures 5

The American College of Chest Physicians recommends obtaining baseline liver function tests, particularly in elderly patients, as 30-40% develop cirrhosis or hepatocellular carcinoma over age 50 4

The American Association for the Study of Liver Diseases advises against overlooking liver disease monitoring, as it affects 30-40% of patients over age 50 and is a significant cause of death in nonsmoking PI*ZZ individuals 4

The American Thoracic Society and European Respiratory Society state that no specific foods or substances need to be avoided in patients with alpha‑1 antitrypsin deficiency; current guidelines do not identify any dietary restrictions. [6][7]8

Smoking cessation is an absolute requirement for all individuals with alpha‑1 antitrypsin deficiency because continued smoking markedly accelerates emphysema progression and shortens life expectancy to < 20 years after diagnosis. This is a strong, evidence‑based recommendation from the American Thoracic Society. 9

Hepatitis A and B vaccination is strongly recommended for all patients with alpha‑1 antitrypsin deficiency, especially those with liver involvement, to prevent additional hepatic injury. 6
Annual influenza and pneumococcal vaccinations are recommended for this population to reduce respiratory infection risk. 8